Effects of Intermittent Fasting Variations on Nutrigenomic Profile, Metabolic Parameters, Inflammation, and Body Composition in Prediabetic Patients

August 6, 2026 updated by: Muhammad Aron Pase

Prediabetes is a metabolic condition associated with increased risk of type 2 diabetes and cardiovascular disease. Intermittent fasting (IF) has emerged as a potential dietary intervention to improve metabolic health, yet comparative evidence among different IF patterns remains limited.

This randomized controlled trial aims to evaluate the effects of three intermittent fasting regimens-5:2 fasting, alternate-day fasting, and time-restricted feeding-compared with a control diet on metabolic parameters, inflammatory markers, body composition, and nutrigenomic profiles in adults with prediabetes.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Indonesia
    • North Sumatera
      • Medan, North Sumatera, Indonesia
        • Department of Internal Medicine - Endocrinology Division, Faculty of Medicine, Universitas Sumatera Utara / RSUP H. Adam Malik Medan
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Patients with prediabetes, defined according to ADA criteria (fasting plasma glucose 100-125 mg/dL or 2-hour postprandial glucose 140-199 mg/dL).
  2. Willing to follow the fasting/diet intervention protocol for 4-6 weeks (depending on the study duration).
  3. Signing informed consent and willing to be randomized into one of 3 intervention groups (Monday-Thursday Fasting/5:2, Alternate-Day Fasting/ADF, or Time-Restricted Fasting/IF).

Exclusion Criteria

  1. Diagnosis of type 2 diabetes mellitus.
  2. Currently undergoing antidiabetic drug therapy (e.g., metformin, sulfonylurea, insulin).
  3. Has a severe chronic disease (kidney failure, liver failure, heart failure, or eating disorder).
  4. Pregnancy or breastfeeding.
  5. History of eating disorders (anorexia nervosa, bulimia nervosa, or binge eating disorder).
  6. Taking medications that affect glucose metabolism (e.g., systemic steroids, atypical antipsychotics, etc.). Diagnosis of type 2 diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intermittent Fasting (16:8)
Behavioral: Diet
Intermittent Fasting
Active Comparator: 5:2 Diet
Behavioral: Diet
Intermittent Fasting
No Intervention: Non Fasting

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Metabolic Profile
Time Frame: Baseline, Week 3, and Week 6
Change in Fasting Plasma Glucose (mg/dL)
Baseline, Week 3, and Week 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lipid Profile
Time Frame: Baseline and Week 6
Concentration Changes of Total Cholesterol
Baseline and Week 6
Lipid Profile
Time Frame: Baseline and Week 6
Concentration Changes of LDL
Baseline and Week 6
Lipid Profile
Time Frame: Baseline and Week 6
Concentration Changes of HDL
Baseline and Week 6
Lipid Profile
Time Frame: Baseline and Week 6
Concentration Changes of Triglycerides
Baseline and Week 6
Nutrigenomics
Time Frame: Baseline
Distribution of Fat Mass and Obesity-Associated gene polymorphism with Enzyme-Linked Immunosorbent Assay method
Baseline
Body Composition
Time Frame: Baseline, Week 3, and Week 6
Change in BMI
Baseline, Week 3, and Week 6
Body Composition
Time Frame: Baseline, Week 3, and Week 6
Change in Waist Circumference
Baseline, Week 3, and Week 6
Inflammation Profile
Time Frame: Baseline and Week 6
Concentration Changes of inflammatory marker (CRP)
Baseline and Week 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Muhammad Aron Pase

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 1, 2026

Primary Completion (Estimated)

October 30, 2026

Study Completion (Estimated)

October 31, 2026

Study Registration Dates

First Submitted

April 25, 2026

First Submitted That Met QC Criteria

August 6, 2026

First Posted (Actual)

August 10, 2026

Study Record Updates

Last Update Posted (Actual)

August 10, 2026

Last Update Submitted That Met QC Criteria

August 6, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • USumateraUtara Prediabetic

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

only IPD used in the results publication

IPD Sharing Time Frame

2026-2030

IPD Sharing Access Criteria

email

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe